Patients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma following platinum-based chemotherapy maintain better health-related quality of life than their counterparts receiving chemotherapy, according to results from the phase III KEYNOTE-045 trial presented at the American Society of Clinical Oncology annual meeting in Chicago.
All corticosteroids matter when it comes to the risk of an intraocular pressure (IOP) response, and that is an important point for ophthalmologists to remember because opportunities for corticosteroid exposure are growing.
A new silicone phacoemulsification sleeve (Ridged Sleeve, ASICO) designed with a variety of novel features is enabling safe and efficient microcoaxial cataract surgery, said Takayuki Akahoshi, MD.
A disposable device for automated anterior capsulotomy that uses precision pulse technology (Zepto, Mynosys Cellular Devices) demonstrated excellent performance in a series of 38 eyes.
Findings from studies investigating intravitreal corticosteroids for treatment of diabetic macular edema (DME) provide information about their efficacy and safety, including some understanding of how they compare with anti-VEGF therapy.
Accumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
Wide-field retinal imaging can be performed using a commercially available swept-source optical coherence tomography (SS-OCT) platform (DRI OCT Triton, Topcon) and only the internal fixation light for patient navigation provided detailed images of both normal and pathologic peripheral retinal findings.
Intravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.
A study aimed at further elucidating the mechanism of action of sipuleucel-T (Provenge) in advanced prostate cancer provides fairly convincing evidence that the immunotherapy agent induces T-cell responses in humans, says Charles G. Drake, MD, PhD.
